hVIVO PLC Broker change (8647Y)

TIDMHVO

RNS Number : 8647Y

hVIVO PLC

08 January 2024

hVIVO plc

("hVIVO" or the "Company")

Appointment of Nominated Adviser and Joint Broker

hVIVO plc (AIM & Euronext: HVO) , the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as Joint Broker with immediate effect.

For further information please contact:

 
 hVIVO plc                                                           [phone] 
 Yamin 'Mo' Khan, Chief Executive 
  Officer 
  Stephen Pinkerton, Chief Financial 
  Officer 
 
 Cavendish Capital Markets Limited (Nominated 
  Adviser and Joint Broker)                                          [phone] 
 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet 
  Ward 
 
 P eel Hunt L LP (Joint Broker)                                       [phone] 
 James Steel, Dr Christopher Golden 
 
 Davy (Euronext Growth Adviser and Joint Broker)                      [phone] 
 Anthony Farrell, Niall Gilchrist 
 
 Walbrook PR (Financial PR & IR)             [phone] or [e-mail] 
  Stephanie Cuthbert / Phillip                    [phone] / [phone] 
  Marriage /                                                                        082 / 
  Louis Ashe-Jepson                                                  [phone] 
 
 

Notes to Editors

About hVIVO

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

Existing Board - AIM Rule 17 Disclosure

The Company announces the following additional director disclosures pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

Elaine Sullivan

In addition to the disclosures made in Elaine Sullivan's announcement of appointment on 24 November 2020, the following directorships are disclosed:

 
 Company                        Current, or last 5 years 
 Carrick Therapeutics Limited   Directorship held in last 5 years, 
                                 at time of appointment to hVIVO 
                               ----------------------------------- 
 

Brendan Buckley

The following directorships were disclosed incorrectly in the Company's Admission Document dated 9 December 2019:

 
 Company                                       Disclosure 
 Irish Platform for Patients' Organisations,   Directorship held more than 5 years 
  Science and Industry Company Limited          prior to publication of the Admission 
                                                Document and therefore should not 
                                                have been disclosed in the Admission 
                                                Document 
                                              --------------------------------------- 
 

Cathal Friel

In addition to the disclosures made in the Admission Document dated 9 December 2019, the following directorships are disclosed:

 
 Company                                    Current, or last 5 years 
 Amryt Pharma Holdings Limited              Directorship held in last 5 years 
                                             at time of Admission Document publication 
                                           ------------------------------------------- 
 Venn Life Sciences Limited                 Current directorship at the time 
  Venn Life Sciences (Germany) GmbH          of Admission Document publication 
  Venn Life Sciences (Ireland) Limited 
  Venn Life Sciences (NI) Limited 
  Venn Life Sciences (Australia) Pty 
  Ltd 
  Venn Life Sciences Inc. 
  Venn Life Sciences Legal Representation 
  B.V 
  Venn Life Sciences ED B.V. 
  Venn Life Sciences (France) SAS 
  Venn Life Sciences B.V. 
                                           ------------------------------------------- 
 

The following directorships were disclosed incorrectly in the Company's Admission Document dated 9 December 2019:

 
 Company                             Current, or last 5 years 
 Amryt Pharma plc                    Incorrectly disclosed as a directorship 
                                    -------------------------------------------- 
 Fastnet Hydrocarbons Limited        Directorship held in last 5 years 
  Raglan Natural Resources Limited    at time of Admission Document publication. 
                                      These directorships were disclosed 
                                      as current directorships in the Admission 
                                      Document 
                                    -------------------------------------------- 
 Fitzwilliam Place Capital Limited   Directorship held more than 5 years 
                                      prior to Admission Document publication 
                                      and therefore should not have been 
                                      disclosed in the Admission Document 
                                    -------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPQKABQBBKDCDK

(END) Dow Jones Newswires

January 08, 2024 02:00 ET (07:00 GMT)